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Abstract: Blood pressure (BP) measurements provide information regarding risk factors 
associated with cardiovascular disease, but only in a speciﬁ  c artery. Arterial stiffness (AS) can 
be determined by measurement of arterial pulse wave velocity (APWV). Separate from any role 
as a surrogate marker, AS is an important determinant of pulse pressure, left ventricular func-
tion and coronary artery perfusion pressure. Proximal elastic arteries and peripheral muscular 
arteries respond differently to aging and to medication. Endogenous human growth hormone 
(hGH), secreted by the anterior pituitary, peaks during early adulthood, declining at 14% per 
decade. Levels of insulin-like growth factor-I (IGF-I) are at their peak during late adolescence 
and decline throughout adulthood, mirror imaging GH. Arterial endothelial dysfunction, an 
accepted cause of increased APWV in GH deﬁ  ciency (GHD) is reversed by recombinant human 
(rh) GH therapy, favorably inﬂ  uencing the risk for atherogenesis. APWV is a noninvasive 
method for measuring atherosclerotic and hypertensive vascular changes increases with age 
and atherosclerosis leading to increased systolic blood pressure and increased left ventricular 
hypertrophy. Aerobic exercise training increases arterial compliance and reduces systolic 
blood pressure. Whole body arterial compliance is lowered in strength-trained individuals. 
Homocysteine and C-reactive protein are two inﬂ  ammatory markers directly linked with arterial 
endothelial dysfunction. Reviews of GH in the somatopause have not been favorable and side 
effects of treatment have marred its use except in classical GHD. Is it possible that we should be 
assessing the combined effects of therapy with rhGH and rhIGF-I? Only multiple intervention 
studies will provide the answer.
Keywords: arterial pulse, wave velocity, arterial stiffness, growth hormone, insulin-like growth 
factor, physiology
Introduction
Arterial distensibility and arterial compliance decrease with age and atherosclerosis 
leading to increased systolic blood pressure (SBP) and a widening of the pulse pressure 
(PP), resulting in left ventricular hypertrophy, a risk factor for cardiovascular disease 
(CVD) (Laogun and Gosling 1982; Riley et al 1986).
Early changes in vascular properties precede the development of coronary artery 
disease (CAD) and hypertensive heart disease (Cohn et al 1995). Arterial pulse wave 
velocity (APWV) and compliance alterations occur early in the course of essential 
hypertension in relation to other CVD risk factors (Brinton et al 1996). Physical 
properties of the vasculature require a measurement of the distending force (ie, BP), 
using pressure transducers at relevant sites (Asmar et al 1995). The form of the pulse 
wave through the walls of the blood vessels is affected by the mechanical properties 
of the vessels. Pulse-wave augmentation results from reﬂ  ections of the pulse wave 
at distal sites (such as bifurcations), such that the forward wave and reﬂ  ected wave 
superimpose producing the typical arterial pulse wave, which differs at different sites Vascular Health and Risk Management 2008:4(6) 1362
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(O’Rourke 1999). The PWV and the amplitude of reﬂ  ected 
waves are increased in stiffer arteries, and are reduced with 
increased arterial compliance (O’Rourke et al 2001). These 
features are dependent on a number of hemodynamic variables, 
including heart rate and PP (Wilkinson et al 2002a). Therefore, 
measurements of augmentation are generally corrected for PP 
and expressed as an “augmentation index” (AIx).
These measurements are also affected by vasoactive drugs 
(O’Rourke 1992; Kelly et al 2001; Wilkinson et al 2001a) 
and by insulin (Westerbacka et al 1999) and are sensitive 
to inhibition of nitric oxide synthase (Kinlay et al 2001; 
Stewart et al 2003). The application of these measurements 
in concert with vasodilators has been proposed as an alter-
native approach for the measurement of vascular function 
(Wilkinson et al 2002b).
Arterial pulse wave velocity
Measurement of arterial wave propagation as an index of 
vascular stiffness and vascular health dates back to the early 
part of the last century (Bramwell and Hill 1922).
The arrival of the pulse wave at two different arterial 
sites is timed, and from estimates of the length of blood 
vessels between these sites (by measuring the distances at 
overlying skin sites), the velocity of this wave is calculated 
in m.s−1 (O’Rourke 1999; Lehmann 1999; Wilkinson et al 
1999). Subtleties come in correctly estimating the intervening 
distances. This provides a reliable measure of arterial stiffness; 
at a given blood pressure, the stiffer the vessel, the less time 
it takes for the pulse wave to travel the length of the vessel. 
The APWV, especially of the aorta, has emerged as an impor-
tant independent predictor of cardiovascular events. APWV 
increases with stiffness and is deﬁ  ned by the Moens–Korteweg 
equation, PWV = √(Eh/2PR), where E is Young’s modulus of 
the arterial wall, h is wall thickness, R is arterial radius at the 
end of diastole, and P is blood density (Lehmann 1999).
The time delay between the arrival of a predeﬁ  ned part of 
the pulse wave, such as the foot, at two points is obtained either 
by simultaneous measurement, or by gating to the peak of the 
R-wave of the ECG. The distance travelled by the pulse wave is 
measured over the body surface and APWV is then calculated 
as distance divided by time (m.s−1) and depends on anatomical 
variation. The abdominal aorta tends to become more tortuous 
with age potentially leading to an underestimation of APWV 
(Wenn and Newman 1990). APWs can also be detected 
by using Doppler ultrasound (Sutton-Tyrrell et al 2001) or 
applanation tonometry (Wilkinson et al 1998b) where the 
pressure within a small micromanometer ﬂ  attened against an 
artery equates to the pressure within the artery. Increases in 
distending pressure increase APWV (Bramwell and Hill 1922). 
Therefore, account should be taken of the level of BP in studies 
that use APWV as a marker of cardiovascular risk.
An increase in HR of 40 beats per minute was shown to 
increase APWV by 1 m/s (Lantelme et al 2002). Also acute 
increases in heart rate (HR) markedly lower arterial disten-
sibility, occurring in both large and middle-size muscular 
arteries within the range of “normal” HR values (Giannattasio 
et al 2003). Raised APWV occurs with a range of established 
cardiovascular risk factors (Lehmann et al 1998) including 
age (Bramwell et al 1923; Vaitkevicius et al 1993), hyper-
cholesterolemia (Lehmann et al 1992a), type II diabetes 
mellitus (DM) (Lehmann et al 1992b), and sedentary lifestyle 
(Vaitkevicius et al 1993). In hypertension, carotid-femoral 
APWV is an independent predictor of both cardiovascular 
and all-cause mortality (Laurent et al 2001). The odds ratio 
for a 5 m.s−1 (a relatively large change in PWV) increment 
in PWV was 1.34 for all-cause mortality and 1.51 for cardio-
vascular mortality. In contrast, PP was independently related 
to all-cause mortality but only marginally related to cardio-
vascular mortality, indicating that speciﬁ  c assessment of 
arterial stiffness, with APWV, may be of greater value in the 
evaluation of risk. APWV ranged from 9 to 13 m.s−1, whereas 
recently quoted values of carotid-femoral PWV in healthy 
individuals with average ages of 24 to 62 years ranged from 
around 6 to 10 m.s−1 (O’Rourke et al 2002). In hypertensive 
subjects without a history of overt cardiovascular disease 
APWV also predicts the occurrence of cardiovascular events 
independently of classic risk factors (Boutouyrie et al 2002). 
Aortic APWV 13 m.s−1 is a particularly strong predictor 
of cardiovascular mortality in hypertension (Blacher et al 
1999a). Carotid-femoral APWV signiﬁ  cantly increases at 
a faster rate in treated hypertensives than in normotensive 
controls, although where BP was well controlled APWV 
progression was attenuated (Benetos et al 2002).
Aortic APWV, assessed by using Doppler ﬂ  ow record-
ings, independently predicts mortality in patients with end-
stage renal failure (ESRF), a population with a particularly 
high rate of cardiovascular disease (Blacher et al 1999b; 
Safar et al 2002). The beneﬁ  t associated with BP control in 
ESRF, by the use of anti-hypertensives, was independently 
related to change in aortic APWV, such that a reduction 
in APWV of 1 m.s−1 was associated with a relative risk of 
0.71 for all-cause mortality (Guerin et al 2001).
The mechanisms of arterial stiffness
Windkessel theory treats the circulation as a central elastic 
reservoir (the large arteries), into which the heart pumps, and Vascular Health and Risk Management 2008:4(6) 1363
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from which blood travels to the tissues through relatively 
nonelastic conduits (Oliver and Webb 2003). The elasticity 
of the proximal large arteries is the result of the high elastin 
to collagen ratio in their walls, which progressively declines 
toward the periphery. The increase in arterial stiffness that 
occurs with age (Hallock and Benson 1937) is the result of 
progressive elastic ﬁ  bre degeneration (Avolio et al 1998). 
The aorta and its major branches are large arteries, which can 
be differentiated from the more muscular conduit arteries, 
such as the brachial and radial arteries. The elasticity of a 
given arterial segment is not constant but instead depends on 
its distending pressure (Hallock and Benson 1937; Greenﬁ  eld 
and Patel 1962). As distending pressure increases, there is 
greater recruitment of relatively inelastic collagen ﬁ  bres 
and, consequently, a reduction in elasticity (Bank et al 
1996). In addition to collagen and elastin, the endothelium 
(Wilkinson et al 2002a) and arterial wall smooth muscle 
bulk and tone (Bank et al 1999) also inﬂ  uence elasticity. 
A number of genetic inﬂ  uences on arterial stiffness have 
also been identiﬁ  ed. Polymorphic variation in the ﬁ  brillin-1 
receptor (Medley et al 2002), angiotensin II type-1 receptor 
and endothelin receptor (Lajemi et al 2001a) genes are 
related to stiffness. The angiotensin-converting enzyme 
(ACE) I/D polymorphism has been associated with stiffness 
(Balkestein et al 2001), but not consistently (Lajemi et al 
2001b). As a consequence of differing elastic qualities and 
wave reﬂ  ection, the shape of the arterial waveform varies 
throughout the arterial tree. In healthy, relatively young 
subjects, whereas mean arterial pressure (MAP) declines in 
the peripheral circulation, SBP and PP are ampliﬁ  ed (Kroeker 
and Wood 1955). This ampliﬁ  cation is exaggerated during 
exercise (Rowell et al 1968) but reduces with increasing age 
(Wilkinson et al 2001). APWV in the brachial artery has 
been shown to increase with age, indicative of worsening 
arterial compliance (Avolio et al 1983). However, brachial 
artery PWV (baPWV) has been reported to change less 
with age than APWV in the aorta or lower limb arteries. In 
contrast, the assessment of distensibility using APWV is 
indirect and potentially affected by changes in blood ﬂ  ow 
and MAP that reﬂ  ect changes in more distal resistance ves-
sels (Nichols and O’Rourke 1998). Atherosclerosis, hyper-
tension, and diabetes produce macro- and micro-vascular 
changes that are reﬂ  ected in vascular function and physical 
properties before the development of overt clinical disease 
(Berenson et al 1992). Endothelial cells continuously release 
nitric oxide (NO), which is synthesized by the endothelial 
isoform of NO synthase (NOS-III) (Moncada et al 1991; 
Förstermann et al 1993). NOS-III activity is stimulated by 
chemical agonists such as serotonin, acetylcholine (ACh) and 
bradykinin (Furchgott 1984; Cocks et al 1985; Newby and 
Henderson 1990) and by ﬂ  ow-induced shear forces on the 
endothelial cell wall (Pohl et al 1986; Busse and Pohl 1993; 
Meredith et al 1996). Endothelium-derived NO diffuses 
toward the underlying vascular smooth muscle, producing 
relaxation. The vascular endothelium, therefore, plays a cen-
tral role in the modulation of arterial smooth muscle tone and 
thus inﬂ  uences large-artery distensibility and the mechanical 
performance of the cardiovascular system (Ramsey et al 
1995). By improving arterial elasticity, endothelium-derived 
NO reduces the arterial wave reﬂ  ection and reduces left 
ventricular work and the pulse pressure within the aorta. 
In addition, exogenous acetylcholine and glyceryl trinitrate 
(GTN) both increase arterial distensibility, the former mainly 
through NO production. This may help explain why condi-
tions that exhibit endothelial dysfunction are also associated 
with increased arterial stiffness. Therefore, reversal of endo-
thelial dysfunction or drugs that are large-artery vasorelax-
ants may be effective in reducing large-artery stiffness in 
humans, and thus cardiovascular risk. GTN reduces brachial 
artery stiffness and decreases wave reﬂ  ection (Yaginuma 
et al 1986). Moreover, drugs that stimulate endothelial NO 
release, such as ACh, also reduce muscular artery stiffness 
in vivo (Ramsey et al 1995; Joannides et al 1997).
Speciﬁ  c studies in exercise
Changes in APWV in dynamic exercise in normal individuals, 
may provide a reference point against which to compare the 
effect of disease states and the basis for evaluation of their 
component mechanisms (Naka et al 2003). Aerobic exercise 
training increases arterial compliance and reduces SBP and 
in cross-sectional studies, aerobically trained athletes have 
a higher arterial compliance than sedentary individuals 
(Mohiaddin et al 1989; Kingwell et al 1995; Vaitkevicius 
et al 1993). Hammer throwers recorded signiﬁ  cantly higher 
compliance in the radial artery of the dominant arm relative 
to both the contra-lateral arm and to an inactive control group 
(Giannattasio et al 1992). This could be explained by the 
dynamic nature of the action.
A single bout of cycling exercise increased whole 
body arterial compliance by mechanisms suggesting 
vasodilation. In exercising muscles, factors including 
local increases in temperature, carbon dioxide, acidity, 
adenosine, NO and magnesium and potassium ions may 
all contribute to local vasodilation (Kingwell et al 1997a). 
Four weeks of cycle training, in sedentary individuals, 
significantly increased forearm blood flow and blood Vascular Health and Risk Management 2008:4(6) 1364
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viscosity, suggesting an increased basal production of 
nitric oxide from the forearm. The elevated shear stress in 
this vascular bed may contribute to endothelial adaptation 
(Kingwell et al 1997b). Both the proximal aorta and the 
leg arteries were significantly stiffer and contributed to 
significantly higher aortic characteristic impedance in 
strength-trained athletes (Bertovic et al 1999). However, 
large-artery stiffening associated with isolated systolic 
hypertension (ISH) is resistant to modification through 
short-term aerobic training (Ferrier et al 2001). In 
subjects 70 to 100 years old, aortic APWV was a strong, 
independent significant predictor of cardiovascular death, 
whereas systolic blood pressure or pulse pressure was 
not (Meaume et al 2001). GTN, an exogenous NO donor 
significantly increased brachial artery area and compli-
ance and significantly decreased pulse wave velocity 
(Kinlay et al 2001). In contrast to the beneficial effect 
of regular aerobic exercise, resistance training does not 
exert beneficial influences on arterial wall buffering func-
tions (Miyachi et al 2003). However, several months of 
resistance training “reduced” central arterial compliance 
in healthy men (Miyachi et al 2004). The 3-hydroxyl-
3-methyl coenzyme A reductase inhibitors (statins), 
significantly reduced total and low-density lipoprotein 
cholesterol and triglyceride levels and increased high 
density lipoprotein cholesterol and significantly lowered 
APWV (Ferrier et al 2002). Atorvastatin significantly 
reduced arterial stiffness in patients with rheumatoid 
arthritis, possibly through an anti-inﬂ  ammatory action 
(Van Doornum et al 2004). Age, blood pressure, body 
mass index (BMI), triglycerides, blood glucose and uric 
acid were shown to be significant variables for baPWV in 
both genders (Tomiyama et al 2003). Central aortic stiff-
ness would appear to be the initial main site for promo-
tion of the development of coronary atherosclerosis and 
ischemic heart disease (McLeod et al 2004).
Physiology of growth hormone (GH)
The ability of the somatotroph cells in the anterior pituitary 
to synthesize and secrete the polypeptide, human growth 
hormone (hGH) are determined by a gene called the Prophet 
of Pit-1 (PROP1). When GH is translated, 70%–80% 
is secreted as a 191-amino-acid, 4-helix bundle protein 
and 20%–30% as a less abundant 176-amino-acid form 
(Baumann 1991) (Figure 1). Hypothalamic-releasing and 
hypothalamic-inhibiting hormones acting via the hypophysial 
portal system control the secretion of GH, which is secreted 
into the circulation (Melmed 2006).
In healthy persons, the GH level is usually 0.2 μg.L−1 
throughout most of the day. There are approximately 10–12 
intermittent bursts in a 24-hour period, mostly at night, 
when the level can rise to 30 μg.L−1 (Melmed 2006). GH 
secretion declines at 14% per decade from the age of 20 
years (Iranmanesh et al 1991).
GH action is mediated by a GH receptor, which is 
expressed mainly in the liver and is composed of dimers 
that change conformation when occupied by a GH ligand 
(Brown et al 2005).
Cleavage of the GH receptor provides a circulating GH 
binding protein (GHBP), prolonging the half-life and medi-
ating the transport of GH. Growth hormone activates the 
growth hormone receptor, to which the intracellular Janus 
kinase 2 (JAK2) tyrosine kinase binds. Both the receptor 
and JAK2 protein are phosphorylated, and signal transduc-
ers and activators of transcription (STAT) proteins bind to 
this complex. STAT proteins are then phosphorylated and 
translocated to the nucleus, which initiates transcription of 
growth hormone target proteins (Argetsinger et al 1993).
Intracellular GH signalling is suppressed by suppres-














































































































































































Figure 1 The structure of human growth hormone. Human growth hormone in its 
correct 22-kD-hGH form. Three-dimensional structure, generated from the protein 
data base SWISS PROT. Structural data supplied with the help of the program RasMol. 
The n-terminal amino acid is at the bottom right hand corner.   The disulphide bridges 
make the molecule a 3 dimensional structure (the sequence range is missing on the 
20 kDa hGH variant).Vascular Health and Risk Management 2008:4(6) 1365
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peripheral insulin-like growth factor I (IGF-I) (Le Roith 
et al 2001) and endocrine, autocrine and paracrine IGF-I 
induces cell proliferation and is thought to inhibit apoptosis 
(O’Reilly et al 2006).
IGF-binding proteins (IGFBP) and their proteases regulate 
the access of ligands to the IGF-I receptor affecting its action. 
Levels of IGF-I are at their peak during late adolescence and 
decline throughout adulthood, mirror imaging GH and are 
determined by sex and genetic factors (Milani et al 2004). 
IGF-I levels reﬂ  ect the secretory activity of growth hormone 
and is a marker for identiﬁ  cation of GH-deﬁ  ciency (GHD), 
or excess (Mauras and Haymond 2005). The production of 
IGF-I is suppressed in malnourished patients, as well as in 
certain disease states, such as liver disease, hypothyroidism, 
or poorly controlled diabetes.
In conjunction with GH, IGF-I has varying differential 
effects on protein, glucose, lipid and calcium metabolism 
and therefore body composition (Mauras et al 2000). Direct 
effects result from the interaction of GH with its speciﬁ  c 
receptors on target cells. In the adipocyte, GH stimulates 
the cell to break down triglyceride and suppresses its ability 
to uptake and accumulate circulating lipids. Indirect effects 
are mediated primarily by IGF-I.
Little is known about the expression of skeletal muscle-
speciﬁ  c isoforms of IGF-I gene in response to exercise in 
humans, nor the inﬂ  uence of age and physical training status. 
A single bout of isometric exercise stimulated the expression 
of mRNA for the IGF-I splice variants IGF-IEa and IGF-IEc 
(mechano growth factor [MGF]) within 2.5 hours, which lasts 
for at least 2 days after exercise (Greig et al 2006).
Gh deﬁ  ciency (GHD)
The therapeutic indications for recombinant human growth 
hormone (rhGH) in the UK are controlled by the National 
Institute for Clinical Excellence guidelines (NICE 2003), 
which has very strict guidelines and has recommended treat-
ment with rhGH for children with:
•  Growth disturbance in short children born small for 
gestational age
•  Proven GH deﬁ  ciency
•  Gonadal dysgenesis (Turner’s syndrome)
• Prader–Willi  syndrome
•  Chronic renal insufﬁ  ciency before puberty (renal function 
decreased to less than 50%).
Treatment should be initiated and monitored by a 
pediatrician with expertise in managing GH disorders; 
treatment can be continued under a shared-care protocol by 
a general practitioner. Treatment should be discontinued if 
the response is poor (ie, an increase in growth velocity of 
less than 50% from baseline) in the ﬁ  rst year of therapy. In 
children with chronic renal insufﬁ  ciency, treatment should 
be stopped after renal transplantation and not restarted for at 
least a year. NICE (2003) has recommended rhGH in adults 
only if the following three criteria are fulﬁ  lled:
•  Severe GH deﬁ  ciency, established by an appropriate 
method
•  Impaired quality of life, measured by means of a speciﬁ  c 
questionnaire
•  Already receiving treatment for another pituitary hormone 
deﬁ  ciency.
Treatment should be discontinued if the quality of life 
has not improved sufﬁ  ciently by nine months. Severe GHD 
developing after linear growth is complete but before the age 
of 25 years should be treated with rhGH; treatment should 
continue until adult peak bone mass has been achieved. 
Treatment for adult-onset GH (A-OGH) deﬁ  ciency should 
be stopped only when the patient and the patient’s physician 
consider it appropriate. Treatment with somatropin should be 
initiated and managed by a physician with expertise in GH 
disorders; maintenance treatment can be prescribed in the 
community under a shared-care protocol (British National 
Formulary 2008). A-OGH deﬁ  cient individuals are over-
weight, with reduced lean body mass (LBM) (Salomon et al 
1989; Amato et al 1993; Beshyah et al 1995) and increased 
fat mass (FM), especially abdominal adiposity (Salomon 
et al 1989; Bengtsson et al 1993; Amato et al 1993; Beshyah 
et al 1995; Snel et al 1995). They have reduced total body 
water (Black et al 1972) and reduced bone mass (Kaufman 
et al 1992; O’Halloran et al 1993; Holmes et al 1994). There 
is also reduced strength and exercise capacity (Cuneo et al 
1990, 1991a, 1991b) and reduced cardiac performance 
and an altered substrate metabolism (Binnerts et al 1992; 
Fowelin et al 1993; Russell-Jones et al 1993; O’Neal et al 
1994; Hew et al 1996). This leads to an abnormal lipid 
proﬁ  le (Cuneo et al 1993; Rosen et al 1993; De Boer et al 
1994; Attanasio et al 1997) which can predispose to the 
development of cardiovascular disease. A-OGH deﬁ  ciency 
reduces psychological well-being and quality of life (QoL) 
(Stabler et al 1992; Rosen et al 1994). The use of rhGH is 
currently being used successfully to treat this deﬁ  ciency.
GH excess (acromegaly)
GH excess results in the clinical condition known as 
acromegaly. This condition is presented as a consequence of 
a pituitary tumor characterized by a multitude of signs and 
symptoms. Pituitary tumors account for approximately 15% of Vascular Health and Risk Management 2008:4(6) 1366
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primary intracranial tumors (Melmed 2006). Acromegalics 
have an increased risk of DM, hypertension and premature 
mortality due to CVD (Bengtsson et al 1993).
The most common side effects following administration 
arise from sodium and water retention.
Weight gain, dependent edema, a sensation of tightness in 
the hands and feet, or carpal tunnel syndrome; can frequently 
occur within days (Hoffman et al 1996).
Arthralgia (joint pain), involving small or large joints can 
occur, but there is usually no evidence of effusion, inﬂ  amma-
tion, or X-ray changes (Salomon et al 1989). Muscle pains 
can also occur. GH administration is documented to result in 
hyperinsulinemia (Hussain et al 1993) which may increase 
the risk of cardiovascular complications. GH-induced 
hypertension (Salomon et al 1989) and atrial ﬁ  brillation 
(Bengtsson et al 1993) have both been reported, but are 
rare. There have also been reports of cerebral side effects, 
such as encephalocele (Salomon et al 1989) and headache 
with tinnitus (Bengtsson et al 1993) and benign intra-cranial 
hypertension (Malozowski et al 1993).
Cessation of GH therapy is associated with regression of 
side effects in most cases (Malozowski et al 1993).
APWV in pathological GH states
The potential mechanisms accounting for this abnormality 
may result from a direct IGF-I mediated effect via increased 
production of NO. Qualitative alterations in lipoproteins have 
been described in GHD adults (O’Neal et al 1996), resulting 
in the generation of an atherogenic lipoprotein phenotype, 
which would contribute to endothelial dysfunction.
Growth hormone deﬁ  ciency (GHD)
Increased oxidative stress exists in GHD adults, which may 
be a factor in atherogenesis and reduced by GH therapy’s 
effects on oxidative stress (Evans et al 2000). Endothelial 
dysfunction exists in GHD adults (Evans et al 1999), which 
is reversible with GH replacement (Pfeifer et al 1999). An 
impaired endothelial-dependent dilatation (EDD) response 
was documented in GHD adults, which significantly 
improved after GH treatment.
Patients with GHD, with increased risk of vascular dis-
ease, have impaired endothelial function and increased AIx 
compared with controls. Replacement of GH resulted in 
improvement of both endothelial function and AIx, without 
changing BP (Smith et al 2002).
Replacement of GH for 3 months corrected endo-
thelial dysfunction in patents with chronic heart failure 
(Napoli et al 2002).
Renal failure induces GH resistance at the receptor 
and post-receptor level, with concomitant endothelial 
dysfunction, which can be overcome by replacement of GH 
(Lilien et al 2004).
Growth hormone excess
Acromegaly is associated with changes in the central arterial 
pressure waveform, suggesting large artery stiffening. This 
may have important implications for cardiac morphology 
and performance as well as increasing the susceptibility to 
atheromatous disease.
Large artery stiffness is reduced in “cured” acromegaly 
(GH  2.5 mU.L−1) and partially reversed after pharmaco-
logical treatment of active disease (Smith et al 2003).
GH and inﬂ  ammatory markers
of CVD
Human peripheral blood T cells, B cells, natural killer (NK) 
cells, and monocytes express IGF-I receptors (Wit et al 
1993). Administration of either GH or IGF-I can reverse the 
immunodeﬁ  ciency of Snell dwarf mice (Van Buul-Offers 
et al 1986). GH replacement induced a signiﬁ  cant overall 
increase in the percent speciﬁ  c lysis of K562 tumor target 
cells, in healthy adults (Crist and Kraner 1990). NK activity 
was signiﬁ  cantly increased throughout the six weeks period 
of administration. In vitro studies, using human lymphocytes 
indicate that GH is important for the development of the 
immune system (Wit et al 1993). However, pre-operative 
administration of GH did not alter C-reactive protein 
(CRP), serum amyloid A (SAA) or interleukin-6 (IL-6, an 
inﬂ  ammatory cytokine) release (Mealy et al 1998). Homo-
cysteine (HCY) concentration has been established as an 
independent risk factor for atherosclerosis (Eichinger et al 
1998; Stehouwer and Jakobs 1998). CRP and IL-6 levels 
and central fat decreased signiﬁ  cantly in rhGH recipients 
in GHD after 18 months. Lipoprotein(a) and glucose 
levels signiﬁ  cantly increased, without affecting lipid levels 
(Sesmilo et al 2000). HCY impairs vascular endothelial 
function through signiﬁ  cant reduction of NO production. 
This appears to potentiate oxidative stress and atherogenic 
development (van Guldener and Stehouwer 2000). HCY 
levels were not signiﬁ  cantly elevated in GHD adults and 
HCY was considered to be unlikely to be a major risk factor 
for vascular disease, if there are no other risk factors present 
(Abdu et al 2001). Pegvisomant (GH receptor antagonist) 
did not induce signiﬁ  cant acute changes in the major risk 
markers for CVD, in apparently healthy abdominally obese 
men (Muller et al 2001). This suggested that the secondary Vascular Health and Risk Management 2008:4(6) 1367
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metabolic changes, eg, inﬂ  ammatory factors, which develop 
as a result of long-standing GHD are of primary importance 
in the pathogenesis of atherosclerosis in patients with GHD. 
Patients with active acromegaly have signiﬁ  cantly lower 
CRP and signiﬁ  cantly higher insulin levels than healthy 
controls and administration of pegvisomant signiﬁ  cantly 
increased CRP to normal levels (Sesmilo et al 2002). 
GH secretory status may be an important determinant of 
serum CRP levels, but the mechanism and signiﬁ  cance of 
this ﬁ  nding is as yet unknown. Inﬂ  ammatory markers are 
predictive of atherosclerosis and cardiovascular events 
(Ridker et al 2002; Danesh et al 2004). The metabolic 
syndrome (MS) is correlated with elevated CRP and a 
predictor of coronary heart disease and DM (Sattar et al 
2003). IL-6 concentrations were signiﬁ  cantly increased in 
GHD, compared to BMI-matched and nonobese controls, 
respectively (Leonsson et al 2003). CRP significantly 
increased in patients compared to nonobese controls, but not 
signiﬁ  cantly different compared to BMI-matched controls. 
Age, LDL-cholesterol, and IL-6 were positively correlated, 
and IGF-I was negatively correlated to arterial intima-media 
thickness (IMT) in the patient group, but only age and IL-6 
were independently related to IMT.
Potential mechanisms
Oxidative stress represents a mechanism leading to the 
destruction of neuronal and vascular cells.
Oxidative stress occurs as a result of the production 
of free radicals or reactive oxygen species (ROS). ROS 
consist of entities including the superoxide anion, hydrogen 
peroxide, superoxide anion, NO, and peroxynitrite. The 
production of ROS, such as peroxynitrite and NO, can lead 
to cell injury through cell membrane lipid destruction and 
cleavage of DNA (Vincent and Maiese 1999). Production of 
excess ROS can result in the peroxidation of docosahexenoic 
acid (DHA), a precursor of neuroprotective docosanoids 
(Mukherjee et al 2004). DHA is a fatty acid released from 
membrane phospholipids and is derived from dietary 
essential fatty acids. It is involved in memory formation, 
excitable membrane function, photoreceptor cell biogenesis 
and function and neuronal signaling. DHA may have a role in 
modulating IGF-I binding in retinal cells (Yorek et al 1989). 
Neuroprotectin D1 (NPD1) is a DHA-derived mediator that 
protects the central nervous system (brain and retina) against 
cell injury-induced oxidative stress, in cerebral ischemia-
reperfusion. It up-regulates the anti-apoptotic Bcl-2 proteins, 
Bcl-2, and Bclxl and decreases pro-apoptotic Bax and Bad 
expression (Bazan 2005).
IGF-I also blocks Bcl-2 interacting mediator of cell death 
(Bim) induction and intrinsic death signalling in cerebellar 
granule neurons (Linseman et al 2002).
Dorsal root ganglia (DRG) neurons express IGF-I receptors 
(IGF-IR), and IGF-I activates the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway. High glucose exposure 
induces apoptosis, which is inhibited by IGF-I through 
the PI3K/Akt pathway. IGF-I stimulation of the PI3K/Akt 
pathway phosphorylates three known Akt effectors: the 
survival transcription factor cyclic AMP response element 
binding protein (CREB) and the pro-apoptotic effector 
proteins glycogen synthase kinase-3beta (GSK-3beta) and 
forkhead (FKHR). IGF-I regulates survival at the nuclear 
level through accumulation of phospho-Akt in DRG neuronal 
nuclei, increased CREB-mediated transcription, and nuclear 
exclusion of FKHR. High glucose levels increase expression 
of the pro-apoptotic Bcl protein Bim (a transcriptional target 
of FKHR). High glucose also induces loss of the initiator 
caspase-9 and increases caspase-3 cleavage, effects blocked 
by IGF-I, suggesting that IGF-I prevents apoptosis in DRG 
neurons by regulating PI3K/Akt pathway effectors, including 
GSK-3beta, CREB, and FKHR, and by blocking caspase 
activation (Leinninger et al 2004).
The unique role of IGF-IR in maintaining the balance 
of death and survival in foetal brown adipocytes, in IGF-IR 
deﬁ  ciency has been demonstrated (Valverde et al 2004).
A vascular protective role for IGF-I has been suggested 
because of its ability to stimulate NO production from 
endothelial and vascular smooth muscle cells. IGF-I probably 
plays a role in aging, atherosclerosis and cerebrovascular 
disease, cognitive decline, and dementia. In cross sectional 
studies, low IGF-I levels have been associated with 
an unfavorable profile of CVD risk factors, such as 
atherosclerosis, abnormal lipoprotein levels and hyperten-
sion, while in prospective studies, lower IGF-I levels predict 
future development of ischemic heart disease. The fall in 
the levels of GH (Iranmanesh et al 1991) and IGF-I (Milani 
et al 2004) with aging correlates with cognitive decline 
and it has been suggested that IGF-I plays a role in the 
development of dementia. IGF-I is highly expressed within 
the brain and is essential for normal brain development. 
IGF-I has anti-apoptotic and neuroprotective effects and 
promotes projection neuron growth, dendritic arborization 
and synaptogenesis (Ceda et al 2005).
Conclusion
Collectively, these data are consistent with a causal link 
between the age-related decline in GH and IGF-I levels and Vascular Health and Risk Management 2008:4(6) 1368
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cardiovascular and cerebrovascular disease in senescence. 
Research into the beneﬁ  ts of replacement hormone therapy 
is still in its infancy. It was only three decades ago that 
rhGH became available and signiﬁ  cant progress into the 
somatopause and related pathologies has occurred. Could 
the future propose the concomitant use of rhGH and rhIGF 
as has been used in certain refractory cases of diabetes 
and GH resistance (Mauras and Haymond 2005)? The 
reviews of rhGH replacement in obesity have not been 
revolutionary (Liu et al 2007). It might be expedient to 
research the combination of rhGH and rhIGF in the variety 
of physiological GHD states to determine any beneﬁ  cial 
effects. After all, it wasn’t until 1999 that hypothyroidism 
was identiﬁ  ed as being more appropriately treated with 
tri-iodothyronine (T3) and tetra-iodothyronine (T4), than 
T4 alone (Bunevicius et al 1999).
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